Mangoceuticals, Inc. (MGRX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mangoceuticals, Inc. (MGRX) trades at $0.5574 with AI Score 17/100 (Grade F). Mangoceuticals, Inc. is a Dallas-based company specializing in men's wellness products, particularly erectile dysfunction treatments, marketed through a telemedicine platform. Market cap: $5.65M, Sector: Healthcare.
Price as of Jul 23, 2026 · Last analyzed: Jun 1, 2026Analyst Coverage for MGRX: MGRX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MGRX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MGRX: 3/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Mangoceuticals, Inc. (MGRX) Healthcare & Pipeline Overview
Mangoceuticals, Inc. leverages telemedicine to provide innovative men's wellness solutions, focusing on erectile dysfunction products marketed under the Mango brand, positioning itself in a growing healthcare niche with a direct-to-consumer approach.
What Is the Investment Thesis for MGRX?
Mangoceuticals, Inc. operates in a niche market with significant growth potential, particularly in men's wellness and erectile dysfunction treatments. The telemedicine platform provides a unique value proposition, allowing for direct consumer engagement and streamlined service delivery. Given the increasing prevalence of erectile dysfunction and the growing acceptance of telehealth, Mangoceuticals is positioned to capture a substantial share of this market. The company's gross margin stands at 52.4%, indicating strong pricing power and operational efficiency, although it currently faces challenges with a profit margin of -4632.9%. As the telemedicine sector continues to expand, Mangoceuticals has the opportunity to enhance its product offerings and scale its operations, potentially leading to improved financial performance in the coming years.
Based on FMP financials and quantitative analysis
MGRX Key Highlights
- Market Cap: $0.00B reflecting early-stage growth potential.
- Profit Margin: -4632.9%, indicating current operational challenges.
- Gross Margin: 52.4%, showcasing strong product pricing capabilities.
- Beta: 2.12, suggesting higher volatility compared to the market.
- Employee Count: 3, indicating a lean operational structure.
Who Are MGRX's Competitors?
MGRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| HIMS Hims & Hers Health, Inc. | $32.74 | +3.35% | $7.30B | 34 |
| CVS CVS Health Corporation | $106.89 | -1.10% | $136B | 76 |
| CMHSF Comprehensive Healthcare Systems, Inc. | $0.34 | +0.00% | $6.22M | 55 |
| CRBKF Carebook Technologies Inc. | $0.03 | +0.00% | $6.84M | 64 |
| CMPD CompuMed, Inc. | $6.70 | -0.30% | $8.64M | 60 |
| BBLN Babylon Holdings Limited | $0.55 | -13.99% | $14.1M | 56 |
| THKKF Think Research Corporation | $0.23 | -1.74% | $17.8M | 57 |
| AKLI Akili, Inc. | $0.43 | +0.25% | $34.1M | 67 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MGRX's Key Strengths?
- Innovative telemedicine platform enhances customer accessibility.
- Strong brand focus on men's wellness products.
- High gross margin reflects effective pricing strategies.
What Are MGRX's Weaknesses?
- Small employee base may limit operational capacity.
- Negative profit margin indicates current financial challenges.
- Limited product range may restrict market appeal.
What Could Drive MGRX Stock Higher?
- Expansion of product offerings to include additional men's wellness solutions.
- Increasing adoption of telehealth services enhancing customer engagement.
- Strategic marketing campaigns aimed at raising brand awareness.
What Are the Key Risks for MGRX?
- Financial-distress signal — its Altman Z-Score of -5.45 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory challenges impacting product approvals and market entry.
- Competition from established players in the telehealth and wellness sectors.
- Economic downturns affecting consumer spending on wellness products.
What Are the Growth Opportunities for MGRX?
- Expansion of Product Line: Mangoceuticals can diversify its offerings by introducing additional men's wellness products, such as supplements and lifestyle aids. The global men's health market is projected to reach $4.5 billion by 2027, providing a substantial opportunity for growth.
- Increasing Telehealth Adoption: As telehealth becomes more mainstream, Mangoceuticals can capitalize on this trend by enhancing its digital platform and marketing strategies. The telemedicine market is expected to grow at a CAGR of 37.7% from 2021 to 2028, indicating a favorable environment for expansion.
- Strategic Partnerships: Collaborating with healthcare providers and pharmacies can enhance Mangoceuticals' distribution channels, improving product accessibility. Partnerships can also bolster credibility and brand recognition in a competitive market.
- Targeted Marketing Campaigns: By leveraging digital marketing strategies, Mangoceuticals can effectively reach its target demographic, increasing brand awareness and customer acquisition. The digital advertising market in healthcare is projected to grow significantly, providing a fertile ground for targeted campaigns.
- International Market Entry: Exploring opportunities in international markets where men's wellness products are in demand can provide Mangoceuticals with new revenue streams. Expanding into regions with growing healthcare access and telemedicine acceptance can enhance the company's market presence.
What Opportunities Does MGRX Have?
- Growing telehealth market presents expansion potential.
- Increasing societal acceptance of men's health discussions.
- Potential for product line diversification.
What Threats Does MGRX Face?
- Intense competition from established healthcare providers.
- Regulatory challenges in the healthcare sector.
- Market volatility may impact financial stability.
What Are MGRX's Competitive Advantages?
- Telemedicine platform provides a unique customer engagement model.
- Focus on men's wellness creates a specialized market niche.
- Strong gross margins indicate effective pricing strategies.
What Does MGRX Do?
Mangoceuticals, Inc., incorporated in 2021, is headquartered in Dallas, Texas, and operates as a subsidiary of Cohen Enterprises, Inc. The company specializes in developing, marketing, and selling men's wellness products, primarily targeting erectile dysfunction through its telemedicine platform. By utilizing an online sales strategy via its website, mangorx.com, Mangoceuticals aims to reach a broad audience seeking discreet and accessible healthcare solutions. The company's product offerings are designed to address a significant and growing market need for men's health, particularly in the realm of sexual wellness. With a small team of three employees, Mangoceuticals emphasizes efficiency and innovation in its operations, aiming to carve out a niche in the competitive healthcare information services sector. The company's focus on telemedicine aligns with broader trends in healthcare towards digital solutions, providing convenience and privacy for its customers. As it continues to grow, Mangoceuticals is positioned to capitalize on the increasing acceptance of telehealth services and the rising demand for men's wellness products.
What Products and Services Does MGRX Offer?
- Develops and markets men's wellness products.
- Offers erectile dysfunction treatments under the Mango brand.
- Utilizes a telemedicine platform for product distribution.
- Sells products directly to consumers via its website, mangorx.com.
- Focuses on providing discreet and accessible healthcare solutions.
- Operates as a subsidiary of Cohen Enterprises, Inc.
How Does MGRX Make Money?
- Generates revenue through the sale of men's wellness products online.
- Utilizes telemedicine to enhance customer engagement and service delivery.
- Focuses on direct-to-consumer sales to maximize margins.
- Leverages digital marketing to reach target demographics effectively.
What Industry Does MGRX Operate In?
The healthcare information services industry is experiencing robust growth, driven by the increasing adoption of telemedicine and digital health solutions. The market for men's wellness products, particularly erectile dysfunction treatments, is expanding as societal attitudes shift towards more open discussions about sexual health. Mangoceuticals, Inc. is positioned within this evolving landscape, competing with established players while leveraging its telemedicine platform to offer unique products directly to consumers. The industry is projected to grow significantly, with telehealth services expected to reach a market size of over $250 billion by 2027, providing ample opportunities for companies like Mangoceuticals.
Who Are MGRX's Key Customers?
- Men seeking solutions for erectile dysfunction.
- Individuals interested in wellness products focused on sexual health.
- Consumers preferring discreet online purchasing options.
How Mangoceuticals, Inc. Is Valued
Mangoceuticals, Inc. carries a market capitalization of $5.65M, placing it in the micro-cap category. Relative to its peer group, MGRX's quantitative score of 17/100 is below the peer average of 58/100.
F-Score 2/9Financial Health
Mangoceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.45 places it in the distress zone, a signal of elevated financial risk.
MGRX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Mangoceuticals' recent insider buying might signal confidence from within, suggesting they believe the company is undervalued. The community seems optimistic about the company's expansion into new markets, anticipating revenue growth. Positive community buzz around their marketing strategies indicates growing brand awareness. The overall market perception seems to be improving as Mangoceuticals gains more visibility and recognition in the telehealth space.
Bear Case
- Recent bearish sentiment in the community highlights concerns about the sustainability of their current business model. Some investors are wary of the company's long-term prospects given the competitive landscape. Negative chatter suggests some believe the market may be overestimating the potential of their products. There's a perception that the company's marketing spend is disproportionate to its revenue, raising concerns about profitability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
MGRX Latest News
-
12 Consumer Staples Stocks Moving In Monday's Pre-Market Session
benzinga · Jul 6, 2026
MGRX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MGRX.
Price Targets
Wall Street price target analysis for MGRX.
MGRX MoonshotScore
What does this score mean?
The MoonshotScore rates MGRX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Jacob D. Cohen
CEO
Jacob D. Cohen is the CEO of Mangoceuticals, Inc., bringing a wealth of experience in the healthcare sector. He has a background in business management and has been involved in various entrepreneurial ventures prior to leading Mangoceuticals. His leadership is characterized by a focus on innovation and market responsiveness.
Track Record: Under Jacob's leadership, Mangoceuticals has established its brand in the men's wellness market, leveraging telemedicine to enhance customer engagement and service delivery. His strategic vision has been pivotal in navigating the early stages of the company's growth.
MGRX Healthcare Stock FAQ
What does the AI Score mean for MGRX?
MGRX holds an AI Score of 17/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Mangoceuticals, Inc. is a Dallas-based company specializing in men's wellness products, particularly erectile dysfunction treatments, marketed through a telemedicine platform. Founded in 2021, it …
What does Mangoceuticals, Inc. do?
Mangoceuticals, Inc. develops and markets men's wellness products, particularly focusing on erectile dysfunction treatments. Utilizing a telemedicine platform, the company sells its products directly to consumers through its website, mangorx.com, providing discreet and accessible healthcare solutions.
What do analysts say about MGRX stock?
Analysts are observing Mangoceuticals, Inc. as a company with potential due to its niche focus on men's wellness and telemedicine. However, concerns about its current financial performance, particularly its negative profit margin, may impact investor sentiment. Analysts are closely monitoring the company's growth strategies and market acceptance.
What are the main risks for MGRX?
Mangoceuticals, Inc. faces several risks, including regulatory challenges that could affect product approvals and market entry. Additionally, the company operates in a highly competitive environment, with established players posing significant threats. Economic downturns may also impact consumer spending on wellness products, further complicating its growth trajectory.
What are the key factors to evaluate for MGRX?
Mangoceuticals, Inc. (MGRX) holds an AI score of 17/100 (low). Not financial advice.
How frequently does MGRX data refresh on this page?
MGRX's price was last updated on Jul 23, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MGRX's recent stock price performance?
Mangoceuticals, Inc. (MGRX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative telemedicine platform enhances customer accessibility. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MGRX overvalued or undervalued right now?
Mangoceuticals, Inc. (MGRX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MGRX before investing?
Before investing in Mangoceuticals, Inc. (MGRX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on available information as of June 2026. Financial metrics may change as the company evolves.